Prosecution Insights
Last updated: May 29, 2026

A2 Biotherapeutics, Inc.

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (20%)
1
Easy (20%)
3
Unknown (60%)

Rejection Statute Mix

BucketCases
§103 only1 (20%)
§112 only1 (20%)
No statute on record3 (60%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WU, JULIE ZHEN QIN 1 61.8% +52.2%
BUTTICE, AUDREY L 1 45.8% +21.5%
CANELLA, KAREN A 1 62.6% +32.9%
SPENCE, JENNIFER SUZANNE 1 65.8% +47.7%
TIWARI, VYOMA SHUBHAM 1 30.2% +46.7%

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18020837 COMPOSITIONS AND METHODS FOR TREATING CANCERS BUTTICE, AUDREY L 121d overdue
18062873 COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS SPENCE, JENNIFER SUZANNE 86d overdue
18165623 COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS CANELLA, KAREN A 46d overdue
18253721 ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY WU, JULIE ZHEN QIN 22d
17480501 CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS TIWARI, VYOMA SHUBHAM 22d

Top Art Units

Art UnitApps
1643 2
1647 1
1633 1
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18253721 ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY WU, JULIE ZHEN QIN 1643 Other Non-Final OA 22d Pending May 19, 2023
18020837 COMPOSITIONS AND METHODS FOR TREATING CANCERS BUTTICE, AUDREY L 1647 §103 Non-Final OA 121d overdue Pending Feb 10, 2023
18165623 COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS CANELLA, KAREN A 1643 Other Non-Final OA 46d overdue Pending Feb 07, 2023
18062873 COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS SPENCE, JENNIFER SUZANNE 1633 Other Non-Final OA 86d overdue Pending Dec 07, 2022
17480501 CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS TIWARI, VYOMA SHUBHAM 1634 §112 Final Rejection 22d Pending Sep 21, 2021

Managing A2 Biotherapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month